ClinicalTrials.gg
RecruitingNCT07878988Updated Nov 3, 2026

This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors

A Phase 1 interventional study of LTZ-232 in Colorectal Cancer, Advanced/Metastatic Solid Tumor and Solid Tumor (Phase I), sponsored by LTZ Therapeutics, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Primary conditionColonic NeoplasmsRegistry: Colorectal NeoplasmsReclassifiedWhy we changed it
Registry
Colorectal Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Colonic Neoplasms
Why
  1. The study's listed conditions name Colonic Neoplasms, a narrower term within Colorectal Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by LTZ Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Updated Nov 3, 2026Start date movedPrimary outcomes revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
152
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,122 studies in Colonic Neoplasms with a site in United States — 116 open to participants now, 190 under way, 14 of them phase 3. Colonic Neoplasms · United States.

Planned enrollment
238th of 864
152 · median 50
Started
2026
with 29 others
Phase 1
244 of 1,122
20 open now
Primary completion
2031-12
later than 179 of 187 live
Registered
1,122nd of 1,122
by date

Among the 1,122 studies in Colonic Neoplasms with a site in United States, this one is the 238th largest by planned enrollment of the 864 interventional ones that give a count, is one of 30 that started in 2026, is one of 244 in phase 1, reaches primary completion later than 179 of the 187 other live ones, and was the 1,122nd registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

116 of the 1,122 studies in Colonic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

110 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 328 Colonic Neoplasms studies recruiting now, 204 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,122 studies in Colonic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a first-in-human, Phase 1, multi-center, open-label study to characterize the safety, pharmacokinetics, pharmacodynamics, and preliminary anti tumor activity of LTZ-232 as monotherapy in adult participants with unresectable or metastatic colorectal cancer and other solid tumors failing standard therapies.

Read the detailed description

LTZ-232 is an engineered anti-EPCAM bispecific antibody designed to activate tumor-associated macrophages to phagocytose and kill tumor cells.

03

Conditions studied

  • Colorectal Cancer
  • Advanced/Metastatic Solid Tumor
  • Solid Tumor (Phase I)
  • EPCAM
  • Colon Cancer

Browse trials for

04

In context

Colonic Neoplasms Reclassified

2,457 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.

This study's planned enrollment of 152 is above the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.

Browse Colonic Neoplasms studies →

Lead sponsor

LTZ Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Compared within Colonic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Colorectal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced / colorectal tumors that have failed standard treatments
  • per (RECIST v1.1)
  • performance status (ECOG PS) ≤ 1
  • Adequate organ function based on laboratory testing

Exclusion criteria

Exclusion Criteria:

  • Active infection with or C
  • Uncontrolled
  • Active disease
  • cardiovascular disease not adequately controlled with medication or impaired function
  • Previous treatment with EpCAM targeting agent
  • Pregnant or breast feeding
  • Non-colorectal active within 3 years that could interfere with study interpretation
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
152 participants (estimated)

Study arms

  • Experimental
    Dose Escalation in metastatic colorectal cancer

    Participants in this arm will participate in one (1) of up to eight (8) escalating defined dose level cohorts. Participants may receive LTZ-232 intravenously up to 24 months unless treatment discontinuation criteria are met.

    Drug: LTZ-232

  • Experimental
    Safety/PK/Pharmacodynamic Cohorts

    Participants may be dosed with LTZ-232 intravenously at levels previously declared safe to further explore safety and clinical activity at particular dose levels.

    Drug: LTZ-232

  • Experimental
    Dose Expansion in metastatic colorectal cancer and other solid tumor types

    Participants with unresectable or metastatic colorectal cancer and other specific solid tumor types at a LTZ-232 dosing regimen(s) identified from dose escalation.

    Drug: LTZ-232

Interventions

  • DrugLTZ-232

    LTZ-232 will be administered intravenously every two weeks for up to 24 months unless treatment discontinuation criteria are met.

07

What researchers measure

Primary outcomes

  1. Characterize the Safety and Tolerability of LTZ-232 in metastatic colorectal cancer and other solid tumors using the incidence, severity, and type of adverse events according to CTCAE v5.0.

    To determine the incidence, severity, and type of adverse events according to NCI and CTCAE v5.0 and assessment of protocol defined dose limiting toxicity criteria.

    Time frame: Up to 24 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2031, 62 months after the start.

Of 51 industry-sponsored phase 1 interventional studies under Colonic Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 64. This study's planned 62 months is above that.

Counting every sponsor, half of 116 studies reached it within 48 months; a quarter within 32 and three quarters within 69.

Start moved once since we started tracking on Sep 25, 2026: Dec 2026 → Oct 2026, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2026
First posted
Oct 16, 2026
StartActual
Oct 28, 2026was Dec 2026
Primary completionEst.
Dec 2031
CompletionEst.
Dec 2031
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Dec 2026→Oct 28, 2026 (actual)
Nov 3, 2026
Interventions
Arm changed Dose Escalation→Dose Escalation in metastatic colorectal cancer; Dose Expansion→Dose Expansion in metastatic colorectal cancer and other solid tumor types
Oct 20, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Safety and TolerabilityNow Characterize the Safety and Tolerability of LTZ-232 in metastatic colorectal cancer and other solid tumors using the incidence, severity, and type of adverse events according to CTCAE v5.0.Time frame: Up to 24 months
Oct 20, 2026
Registered
First appeared on the registry
Oct 16, 2026
Show all 3 updates
  1. Nov 3, 2026
    Start date Dec 2026→Oct 28, 2026 (now actual)
  2. Oct 20, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Safety and TolerabilityNow Characterize the Safety and Tolerability of LTZ-232 in metastatic colorectal cancer and other solid tumors using the incidence, severity, and type of adverse events according to CTCAE v5.0.Time frame: Up to 24 months
    Interventions Arm changed Dose Escalation→Dose Escalation in metastatic colorectal cancer; Dose Expansion→Dose Expansion in metastatic colorectal cancer and other solid tumor types
  3. Oct 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07878988
Lead sponsor
LTZ Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 16, 2026
Start date
Oct 28, 2026
Primary completion
Dec 2031 (estimated)
Completion
Dec 2031 (estimated)
Last update
Nov 3, 2026

Study contacts

Sherry Unabia
Contact
sherry.unabia@ltztherapeutics.com
669-207-0084

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion